Antineuthropil cytoplasmic autoantibody-associated vasculitis (AAV) in older patients (REVAS Study)

Treatment of Systemic Necrotizing Vasculitides in Patients Aged Sixty‐Five Years or Older: Results of a Multicenter, Open‐Label, Randomized Controlled Trial of Corticosteroid and Cyclophosphamide–Based Induction Therapy

“…Reasons for those findings are various and may include longer diagnostic delay (leading to greater disease severity at diagnosis) and higher susceptibility to developing SAEs due to physiologic aging and comorbidities. Mortality was 6.7% during induction and reached 20% at 3 years in the present trial, compared to 30.2% at 5 years in our previous retrospective study of patients aged 65 years or older , and 32.1% in REVAS . For comparison, mortality of SNV populations of all ages was 15% at 2 years, and 22% at 5 years, in the European Vasculitis Study Group (EUVAS) long‐term followup study .…”

“…Older SNV patients are more fragile and their outcomes were reported to be worse than those of younger populations in previous series . A recent retrospective study from Spain (Registro Español de Vasculitis Sistémicas [REVAS]) and our own findings showed that SNV in this older population is severe at diagnosis, often with advanced renal involvement, and high treatment‐related morbidity and mortality . Reasons for those findings are various and may include longer diagnostic delay (leading to greater disease severity at diagnosis) and higher susceptibility to developing SAEs due to physiologic aging and comorbidities.…”

The European Vasculitis Society 2016 Meeting Report

“…The increasing clinical trial activity in the field of vasculitis, the need to collect long-term data on biologic treatment safety and efficacy in routine care, and the wide variety of clinical manifestations in this group of rare diseases, has led to the development of several vasculitis registries across Europe. Eight European countries have already established such registries (Czech Republic, France, Ireland, Norway, Poland, Portugal, Spain, and the United Kingdom 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 ). In many other countries, this topic is on their research and clinical agendas (e.g., Germany, Switzerland, and the Netherlands).…”